Personaliseret ultralyds hjernestimulering til depression (R61)
Personaliseret ultralyds hjernestimulering til depression: En undersøgelse af målengagement og humørvirkninger
This study will evaluate a new form of non-invasive brain stimulation for individuals with depression. Personalized low-intensity transcranial focused ultrasound stimulation will be delivered using a range of stimulation parameters during psychological and physiological monitoring. Individualized optimal targets will be selected using structural MRI and diffusion tractography. Brain target engagement will be evaluated using functional MRI.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
This R61 project has 3 aims:
- To determine whether stimulation engages the subcallosal cingulate (SCC) in an intensity-dependent manner
- To examine the degree of specificity of neuromodulation by contrasting the neural effects of stimulating two spatially distinct targets versus sham
- To evaluate safety, tolerability, and side effects
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84108
- University of Utah
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age 18-65, any gender.
- Primary diagnosis of DMS-5 major depressive disorder (MINI).
- Current moderate-to-severe depressive episode, without psychotic features, lasting at least 2 months (MINI).
- Self-rated 16-item Quick Inventory of Depressive Symptomatology (QIDS) total score > 10.
- History of at least 2 failed trials of evidence-based antidepressant medication and/or psychotherapy (at least one trial during the current depressive episode).
- Stated willingness to comply with all study procedures and avoid changes to psychiatric treatments (medications, psychotherapy) for the duration of the study.
- For participants of reproductive potential: negative pregnancy test or use of highly effective contraception for at least 1 month prior to baseline; agreement to use such a method throughout the study.
- Capacity to provide informed consent; provision of a signed and dated consent form
- Currently are under the care of a licensed psychiatrist or other mental health care provider, or a licensed addiction medicine specialist and agrees to promptly inform the investigator or the study staff of any change in these providers.
- Agrees to allow any and all forms of communication between the investigators/study staff and any healthcare provider who currently provides and/or has provided service to the patient/subject within at least two years of study enrollment for the purposes of eligibility confirmation or in case of a safety event.
- Agrees to provide the name and verifiable contact information (email and mailing addresses, mobile and land-line phone numbers, as applicable) of at least two persons 22 years or older who reside within a 60-minute drive of the patient's residence. Subject agrees that in the event of a safety concern or event during study participation, research staff is at liberty to contact these individuals if the subject does not respond to contact attempts.
Exclusion Criteria:
- History of serious brain injury or other neurologic disorder.
- Poorly managed general medical condition.
- Pregnant or breast feeding.
- Implanted device in the head or neck.
- MRI intolerance or contraindication.
- Brain stimulation treatment such as ECT, TMS, or VNS (past month).
- Recent change in antidepressant treatments (past month).
- 8. Moderate-High Risk of Suicide according to the Columbia - Suicide Severity Rating Scale (C-SSRS) Screen Version - Recent (answers YES to Question 3 and NO to Question 6 (Moderate risk) or YES to Question 4, 5, or 6 (High risk)) and/or in the clinical judgement of the PI or a study psychiatrist
- Suicidal behavior (past year).
- Serious suicide attempt 33 (lifetime).
- Moderate-to-severe substance use disorder (MINI, past 3 months).
- Obsessive compulsive disorder, primary diagnosis (MINI, past month).
- Posttraumatic stress disorder, primary diagnosis (MINI, past month).
- Bipolar-spectrum disorder (MINI, lifetime).
- Schizophrenia-spectrum disorder (MINI, lifetime).
- Neurocognitive disorder (DSM-5, past year).
- Severe personality disorder.
- Clinically inappropriate for participation in the study as determined by the study team.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Tredobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Group 1: SCC-ALIC
Low-intensity transcranial focused ultrasound stimulation (LTFUS) is delivered to the subgenual cingulate cortex (SCC) at the first stimulation visit, then LTFUS is delivered to the anterior limb of the internal capsule (ALIC) at the second stimulation visit. |
Low-intensity transcranial focused ultrasound delivered to subgenual cingulate cortex Low-intensity transcranial focused ultrasound delivered to anterior limb of internal capsule |
|
Eksperimentel: Group 2: ALIC-SCC
Low-intensity transcranial focused ultrasound stimulation (LTFUS) is delivered to the anterior limb of the internal capsule (ALIC) at the first stimulation visit, then LTFUS is delivered to the subgenual cingulate cortex (SCC) at the second stimulation visit. |
Low-intensity transcranial focused ultrasound delivered to subgenual cingulate cortex Low-intensity transcranial focused ultrasound delivered to anterior limb of internal capsule |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Modulation of SCC activity during SCC stimulation
Tidsramme: Days 14, 21, 28
|
Functional MRI is used to quantify modulation of SCC activity during SCC stimulation |
Days 14, 21, 28
|
|
Modulation of SCC activity during ALIC stimulation
Tidsramme: Days 14, 21
|
Functional MRI is used to quantify modulation of SCC activity during ALIC stimulation |
Days 14, 21
|
|
Study dropout
Tidsramme: From enrollment to the end of participation at 7 weeks
|
Dropout or withdrawal due to stimulation-related adverse effects |
From enrollment to the end of participation at 7 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
PANAS-X
Tidsramme: Immediately before and after each LTFUS on Days 14, 21, 28
|
Positive and Negative Affect Schedule, Expanded Form |
Immediately before and after each LTFUS on Days 14, 21, 28
|
|
MADRS
Tidsramme: Days 14, 21, 28, 35, 49
|
Montgomery-Asberg Depression Rating Scale |
Days 14, 21, 28, 35, 49
|
|
HDRS-6
Tidsramme: Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
6-item Hamilton Depression Rating Scale |
Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
|
IDS-SR
Tidsramme: Days 0, 14, 21, 28, 35, 49
|
Inventory of Depressive Symptomatology, Self-Rated |
Days 0, 14, 21, 28, 35, 49
|
|
GAD-7
Tidsramme: Days 0, 14, 21, 28, 35, 49
|
7-item Generalized Anxiety Disorder Scale |
Days 0, 14, 21, 28, 35, 49
|
|
YMRS
Tidsramme: Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
Young Mania Rating Scale |
Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
|
C-SSRS
Tidsramme: Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
Columbia Suicide Severity Rating Scale, Screen Version |
Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
|
GASE
Tidsramme: Days 15, 22, 29
|
Generic Assessment of Side Effects scale |
Days 15, 22, 29
|
|
MoCA
Tidsramme: Days 14, 15, 49
|
Montreal Cognitive Assessment |
Days 14, 15, 49
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Brian J Mickey, University of Utah
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- IRB_00148802R61
- R61MH134943 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .